大麻使用障碍药物治疗的进展：一项基于证据的综述。
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.
作者信息
Copeland Jan, Pokorski Izabella
机构信息
UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.
出版信息
Subst Abuse Rehabil. 2016 May 3;7:41-53. doi: 10.2147/SAR.S89857. eCollection 2016.
Abstract
Cannabis is the most widely used and variably regulated drug in the world, with increasing trends of use being reported in the US, Australia, Asia, and Africa. Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users. Cannabis use is associated with numerous health risks and long-term morbidity, as well as risk of developing cannabis-use disorders. Cannabis users infrequently seek professional treatment, and normally do so after a decade of use. Cannabis-use disorders are currently treated using a selection of psychosocial interventions. Severity of withdrawal is a factor that increases the risk of relapse, and is the target of pharmacotherapy studies. Currently, there is no approved pharmacotherapy for cannabis-use disorders. A number of approaches have been examined, and trials are continuing to find a safe and effective medication with little abuse liability.
摘要
大麻是世界上使用最广泛且管制差异很大的毒品，美国、澳大利亚、亚洲和非洲都报告有使用趋势增加的情况。有证据表明，在一些发达国家，开始使用大麻的年龄有所下降，而且在较新的使用者中，开始使用大麻的风险期延长至青春期之后。使用大麻与众多健康风险和长期发病率相关，还与患大麻使用障碍的风险有关。大麻使用者很少寻求专业治疗，通常在使用十年后才这样做。目前使用一系列心理社会干预措施来治疗大麻使用障碍。戒断的严重程度是增加复发风险的一个因素，也是药物治疗研究的目标。目前，尚无获批用于治疗大麻使用障碍的药物疗法。已经研究了多种方法，并且仍在继续进行试验，以找到一种几乎没有滥用可能性的安全有效的药物。
相似文献
1
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.大麻使用障碍药物治疗的进展：一项基于证据的综述。
Subst Abuse Rehabil. 2016 May 3;7:41-53. doi: 10.2147/SAR.S89857. eCollection 2016.
3
Pharmacotherapies for cannabis dependence.大麻依赖的药物治疗
Cochrane Database Syst Rev. 2019 Jan 28;1(1):CD008940. doi: 10.1002/14651858.CD008940.pub3.
4
Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?大麻素治疗大麻使用障碍：接触和帮助青少年的新途径？
Neurosci Biobehav Rev. 2022 Jan;132:169-180. doi: 10.1016/j.neubiorev.2021.11.033. Epub 2021 Nov 22.
5
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.大麻戒断症状的大麻素激动剂替代疗法疗效的系统评价。
CNS Drugs. 2018 Dec;32(12):1113-1129. doi: 10.1007/s40263-018-0577-6.
6
Pharmacotherapies for cannabis dependence.大麻依赖的药物治疗。
Cochrane Database Syst Rev. 2014;12(12):CD008940. doi: 10.1002/14651858.CD008940.pub2. Epub 2014 Dec 17.
7
When and How to Treat Possible Cannabis Use Disorder.何时以及如何治疗可能的大麻使用障碍。
Med Clin North Am. 2018 Jul;102(4):667-681. doi: 10.1016/j.mcna.2018.02.009.
8
Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review.治疗精神分裂症或抑郁症患者的大麻使用问题：系统评价。
J Clin Psychiatry. 2010 Mar;71(3):247-54. doi: 10.4088/JCP.09r05119gry.
9
[Motivational interviewing for cannabis users with psychotic disorders].[针对患有精神障碍的大麻使用者的动机性访谈]
Encephale. 2007 Oct;33(5):819-26. doi: 10.1016/j.encep.2006.08.001.
10
Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report.成人大麻戒断的心理和社会心理干预：系统评价简短报告
Health Technol Assess. 2015 Jul;19(56):1-130. doi: 10.3310/hta19560.
引用本文的文献
1
Development of Mobile Contingency Management for Cannabis Use Reduction.开发移动应急管理以减少大麻使用。
Behav Ther. 2024 Jan;55(1):1-13. doi: 10.1016/j.beth.2023.03.004. Epub 2023 Apr 5.
2
Interventions for cannabis use disorder.大麻使用障碍的干预措施。
Curr Opin Psychol. 2021 Apr;38:67-74. doi: 10.1016/j.copsyc.2020.11.002. Epub 2020 Nov 17.
3
Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.HIV 和大麻素对大脑和认知功能的相互影响。
J Neuroimmune Pharmacol. 2020 Dec;15(4):765-779. doi: 10.1007/s11481-020-09921-y. Epub 2020 May 22.
4
Clinical Practice Guidelines on Assessment and Management of Substance Abuse Disorder in Children and Adolescents.儿童和青少年物质使用障碍评估与管理临床实践指南
Indian J Psychiatry. 2019 Jan;61(Suppl 2):333-349. doi: 10.4103/psychiatry.IndianJPsychiatry_581_18.
5
Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology.外源性孕激素治疗女性大麻戒断：一种新的多模态方法的可行性试验。
Pharmacol Biochem Behav. 2019 Apr;179:22-26. doi: 10.1016/j.pbb.2019.01.008. Epub 2019 Jan 31.
6
An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use.大麻使用障碍的最新进展，并就与治疗和娱乐性大麻使用相关的政策影响发表评论。
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):73-86. doi: 10.1007/s00406-018-0976-1. Epub 2019 Jan 2.
7
Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.在美国，平均效力较高与首次大麻使用障碍症状进展相关。
Drug Alcohol Depend. 2019 Feb 1;195:186-192. doi: 10.1016/j.drugalcdep.2018.11.012. Epub 2018 Dec 17.
8
Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.大麻二酚调节自发大麻戒断引起的行为改变和基因表达变化。
Br J Pharmacol. 2018 Jul;175(13):2676-2688. doi: 10.1111/bph.14226. Epub 2018 May 3.
9
Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.重度使用大麻的青少年和年轻人中托吡酯耐受性的预测因素：一项随机、双盲、安慰剂对照试验的二次分析
J Clin Psychopharmacol. 2018 Apr;38(2):134-137. doi: 10.1097/JCP.0000000000000843.
10
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.纳布西莫尔联合动机增强/认知行为疗法治疗大麻依赖：一项随机临床试验试点研究
PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018.
本文引用的文献
1
Vilazodone for cannabis dependence: A randomized, controlled pilot trial.维拉唑酮治疗大麻依赖：一项随机对照试验性研究。
Am J Addict. 2016 Jan;25(1):69-75. doi: 10.1111/ajad.12324. Epub 2015 Dec 20.
2
Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.2001 - 2002年至2012 - 2013年期间美国大麻使用障碍的患病率。
JAMA Psychiatry. 2015 Dec;72(12):1235-42. doi: 10.1001/jamapsychiatry.2015.1858.
3
Cannabidiol as a Potential Treatment for Anxiety Disorders.大麻二酚作为焦虑症的一种潜在治疗方法。
Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1.
4
Natural outcome of cannabis use disorder: a 3-year longitudinal follow-up.大麻使用障碍的自然转归：一项为期3年的纵向随访研究
Addiction. 2015 Dec;110(12):1963-74. doi: 10.1111/add.13071. Epub 2015 Aug 26.
5
Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.大麻素替代疗法（CRT）：纳布西莫尔（Sativex）作为大麻戒断的一种新型治疗方法。
Clin Pharmacol Ther. 2015 Jun;97(6):571-4. doi: 10.1002/cpt.109. Epub 2015 Apr 17.
6
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.治疗大麻使用障碍的新型药理学方法。
Curr Addict Rep. 2014 Jun 1;1(2):137-143. doi: 10.1007/s40429-014-0011-1.
7
Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting.碳酸锂用于大麻戒断管理：一项住院环境下的随机安慰剂对照试验
Psychopharmacology (Berl). 2014 Dec;231(24):4623-36. doi: 10.1007/s00213-014-3611-5. Epub 2014 Jun 1.
8
Misuse and abuse of pregabalin and gabapentin: cause for concern?普瑞巴林和加巴喷丁的误用和滥用：值得关注吗？
CNS Drugs. 2014 Jun;28(6):491-6. doi: 10.1007/s40263-014-0164-4.
9
Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder.患有大麻使用障碍的戒断青少年的智力、神经认知和学业成就。
Psychopharmacology (Berl). 2014 Apr;231(8):1467-77. doi: 10.1007/s00213-014-3463-z. Epub 2014 Mar 12.
10
Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health.美国酒精和大麻使用障碍的患病率及其相关因素：青少年健康全国纵向研究的结果
Drug Alcohol Depend. 2014 Mar 1;136:158-61. doi: 10.1016/j.drugalcdep.2013.11.022. Epub 2013 Dec 14.
Zotero 插件